SYRS Syros Pharmaceuticals


Data from SEC filings
Employee count

ESG framework mentions

In last year of SEC filings
Sustainability Accounting Standards Board (SASB)
No mentions
Global Reporting Initiative (GRI)
No mentions
Task Force on Climate-related Financial Disclosures (TCFD)
No mentions
UN Sustainable Development Goals (SDGs)
No mentions

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM
The Company held its annual meeting of stockholders on June 8, 2021 (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted in the following manner with respect to the following proposals:

1.The election of three Class II directors, each to serve for a three-year term expiring at the 2024 annual meeting of stockholders and until his successor has been duly elected and qualified.

NomineesForWithheldBroker Non-Votes
Srinivas Akkaraju, M.D., Ph.D.37,137,7697,043,7278,483,036
Phillip A. Sharp, Ph.D.38,015,9376,165,5598,483,036
Richard A. Young, Ph.D.37,506,3886,675,1088,483,036

2.The ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021.